Hickman Ingrid J, Macdonald Graeme A
Diamantina Institute for Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Am J Med. 2007 Oct;120(10):829-34. doi: 10.1016/j.amjmed.2007.03.025.
The prevalence of type 2 diabetes is higher in patients who have liver diseases, such as nonalcoholic fatty liver disease, chronic viral hepatitis, hemochromatosis, alcoholic liver disease, and cirrhosis. The development of diabetes in patients with cirrhosis is well recognized, but evidence is emerging that the development of chronic liver disease and progression to cirrhosis may occur after the diagnosis of diabetes and that diabetes plays a role in the initiation and progression of liver injury. This article provides an overview of the evidence for an increased prevalence of diabetes in a range of liver diseases; the effect of diabetes on the severity of disease; the potential mechanisms whereby coexistent diabetes exacerbates progression of hepatic fibrosis; and the impact of obesity, insulin resistance, and type 2 diabetes on clinical outcomes.
2型糖尿病在患有肝脏疾病的患者中患病率更高,这些肝脏疾病包括非酒精性脂肪性肝病、慢性病毒性肝炎、血色素沉着症、酒精性肝病和肝硬化。肝硬化患者中糖尿病的发生已得到充分认识,但越来越多的证据表明,慢性肝病的发生以及向肝硬化的进展可能在糖尿病诊断之后出现,并且糖尿病在肝损伤的起始和进展中起作用。本文概述了一系列肝脏疾病中糖尿病患病率增加的证据;糖尿病对疾病严重程度的影响;共存糖尿病加剧肝纤维化进展的潜在机制;以及肥胖、胰岛素抵抗和2型糖尿病对临床结局的影响。